A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Phase 2RecruitingNCT06157827

Nanjing Leads Biolabs Co.,Ltd178 enrolled

Overview

An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)

This trial includes two parts: phase Ib and phase II study. Phase Ib is a dose-escalation and Phase II is the dose optimization and dose expansion . Phase Ib program to enroll patients with advanced neuroendocrine carcinoma (NEC) without systemic therapy.To sequentially evaluate the safety and tolerability of LBL-024 in combination with etoposide and platinum (cisplatin or carboplatin) at different doses by the dose-escalation method. Phase II includes two stages, dose optimization and dose expansion. The dose optimization part will conduct combination of LBL-024, which is a further optimization study in two dose groups, enrolling patients with EP-NEC who have not received systemic treatment, to fully assess the dose-exposure-effect relationship, and in combination with the target binding characteristics of LBL-024, pharmacokinetic/pharmacodynamic, efficacy and/or safety profile, considering multiple dimensions,To confirm the rationale for the recommended Phase 2 dose (RP2D). The dose expansion:the recommended Phase 2 dose (RP2D) will be determined based on the safety, tolerability, efficacy and PK data from the clinical studies of LBL-024.After obtaining the RP2D, a dose expansion study of combination dosing at the RP2D will be conducted to obtain adequate efficacy data. This trial will enroll 178 patients in Phase Ib and Phase II study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

178

Conditions

Advanced Neuroendocrine Carcinoma

Interventions

LBL-024 for InjectionDRUG

intravenous infusion

Etoposide InjectionDRUG

intravenous infusion

Carboplatin InjectionDRUG

intravenous infusion

Atezolizumab injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent. 2. aged 18-75 years (including borderline values) at the time of signing the informed consent form 3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1. 4. The expected survival time is at least 12 weeks. 5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable target lesion. 6. Fertile men and women of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug. Exclusion Criteria: 1. Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period 2. Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon 3. Subjects with an active infection that currently requires intravenous anti-infective therapy. 4. Clinically uncontrollable pleural effusion, pericardial effusion, and requiring repeated drainage or medical intervention. 5. medical history of immunodeficiency including HIV antibody positive. 6. Pregnant or lactating women. 7. The investigator believes that the subject has other conditions that may affect compliance or that are not suitable for participating in this study.

Locations (25)

Outcomes

Primary Outcomes

Objective Response Rate (ORR)

ORR (including the rates of complete response (CR) and partial response (PR)), evaluated based on the RECIST 1.1, refers to the percentage of study subjects who achieve a complete response or partial response. It was used to evaluate the efficacy in Phase II .

Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy).

Dose-limiting toxicities（DLT）

DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. It was used to evaluate the safety in Phase Ib.

Time frame: Within 3 weeks after receiving the first dose of the test drug (DLT assessment for subjects in dose escalation phase).

Progression-Free Survival(PFS)

PFS is defined as the time from randomization to disease progression or death from any cause.It was used to evaluate the efficacy in Phase II .

Occurrence of adverse event (AE) and serious adverse event (SAE)

Adverse event (AE) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0.The safety profile of LBL-024 Combination Administration will be assessed by monitoring the adverse event (AE) and serious adverse event (SAE) in Phase Ib study.

Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)

The recommended Phase 2 dose (RP2D)

The recommended Phase 2 dose (RP2D) will be determined comprehensively based on the safety, tolerability, efficacy and PK data from the clinical studies of LBL-024 in advance.

Central Contacts

lin shen

CONTACT

025-83378099 kongxue@leadsbiolabs.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Anhui Provincial Hospital

Hefei, Anhui, China

RECRUITING

Anhui Cancer Hospital

Hefei, Anhui, China

RECRUITING

Beijing GoBroad Hospital

Beijing, Beijing Municipality, China

RECRUITING

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

RECRUITING

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

RECRUITING

Fujian Cancer Hospital

Fuzhou, Fujian, China

RECRUITING

Sun Yat-sen University Cancer Center (SYSUCC)

Guangzhou, Guangdong, China

RECRUITING

The First Affiliated Hospital of Guangdong Pharmaceutical University

Guangzhou, Guangdong, China

RECRUITING

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

RECRUITING

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

RECRUITING

...and 15 more locations

Secondary Outcomes

Cmax

Maximum serum concentration

Tmax

After taking a single dose, Time to reach maximum plasma concentration

immunogenicity

The immunogenicity is evaluated by the incidence of anti-drug antibodies (ADA) and neutralizing antibodies (if applicable) in subjects

Duration of Response(DOR）

The period from the participants first achieving CR or PR to disease progression.

Disease Control Rate(DCR)

Percentage of participants achieving CR, PR, iCR, iPR and stable disease (SD) after treatment.